AGRA
Acellular Growth Retardation Ability
Determination of the state of the humoral immune system in patients with liver disease.
Background
Bacterial infections in patients with cirrhosis are a frequent and life-threatening complication, which are difficult to predict.
Clinical Need
Currently, it is not possible to reliably predict susceptibility and the risk of infection in cirrhosis. Therefore, tools to predict severe infections are an urgent clinical need and will help to reach the goal of precision medicine.
Our Solution
We invented AGRA, a reliable, easy-to-assess, functional biomarker with the possibility for fully automated handling that utilizes the growth tendencies of a specific strain of bacteria in human serum to predict the outcome of a patient.
Effects and Benefits
AGRA predicts the occurrence of severe infections in patients with liver cirrhosis, accurately identifies patients at risk of infections, tracks treatment success and helps to create personalized risk-assessment and treatment of patients with liver cirrhosis.
We believe in further applications of AGRA beyond liver disease and are actively looking for partners to join our research.
